Editorial
Infants and Proton Pump Inhibitors: Tribulations, No Trials
Susan R Orenstein,
Eric Hassall,
Corresponding Author
Susan R Orenstein
Division of Pediatric Gastroenterology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Address correspondence and reprint requests to Susan R. Orenstein, MD, University of Pittsburgh School of Medicine, 303 Church Lane, Pittsburgh, PA 15238-1006 (e-mail: [email protected], or [email protected]).Search for more papers by this authorEric Hassall
Division of Gastroenterology, BC Children's Hospital/University of British Columbia, Vancouver, BC, Canada
Search for more papers by this authorSusan R Orenstein,
Eric Hassall,
Corresponding Author
Susan R Orenstein
Division of Pediatric Gastroenterology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Address correspondence and reprint requests to Susan R. Orenstein, MD, University of Pittsburgh School of Medicine, 303 Church Lane, Pittsburgh, PA 15238-1006 (e-mail: [email protected], or [email protected]).Search for more papers by this authorEric Hassall
Division of Gastroenterology, BC Children's Hospital/University of British Columbia, Vancouver, BC, Canada
Search for more papers by this authorDr Orenstein has received research grant support from and/or has consulted to AstraZeneca, TAP, Wyeth, McNeil, Janssen, SmithKline Beecham, Merck, GlaxoSmithKline, Reliant, and Braintree Laboratories. Dr Hassall is the recipient of a research grant from AstraZeneca, and has consulted to TAP and Abbott Canada.
REFERENCES
- 1Barron JJ, Tan H, Spalding J, et al. Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr 2007; 45: 421–427.
- 2Foroutan HR, Ghafari M. Gastroesophageal reflux as cause of chronic respiratory symptoms. Indian J Pediatr 2002; 69: 137–139.
- 3Ay M, Sivasli E, Bayraktaroglu Z, et al. Association of asthma with gastroesophageal reflux disease in children. J Chin Med Assoc 2004; 67: 63–66.
- 4Ciftci E, Gunes M, Koksal Y, et al. Underlying causes of recurrent pneumonia in Turkish children in a university hospital. J Trop Pediatr 2003; 49: 212–215.
- 5Yuksel H, Yilmaz O, Kirmaz C, et al. Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease. Respir Med 2006; 100: 393–398.
- 6Colletti RB, Hassall E, Heyman MB, et al. Use of proton pump inhibitors (PPIs) by pediatric gastroenterologists [abstract]. J Pediatr Gastroenterol Nutr 2001; 33: 414.
- 7Hassall E. Mistaking “life” (as we know it) for “disease”. Am J Gastroenterol 2006; 101: 2434–2436.
- 8Moore DJ, Tao BS, Lines DR, et al. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr 2003; 143: 219–223.
- 9Omari TI, Haslam RR, Lundborg P, et al. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J Pediatr Gastroenterol Nutr 2007; 44: 41–44.
- 10Orenstein SR, Shalaby TM, Kelsey SF, et al. Natural history of infant reflux esophagitis: symptoms and morphometric histology during one year without pharmacotherapy. Am J Gastroenterol 2006; 101: 628–640.
- 11Kleinman L, Rothman M, Strauss R, et al. The infant gastroesophageal reflux questionnaire revised: development and validation as an evaluative instrument. Clin Gastroenterol Hepatol 2006; 4: 588–596.
- 12Kleinman L, Revicki DA, Flood E. Validation issues in questionnaires for diagnosis and monitoring of gastroesophageal reflux disease in children. Curr Gastroenterol Rep 2006; 8: 230–236.
- 13Orenstein SR, Shalaby TM, Devandry SN, et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment Pharmacol Ther 2003; 17: 1097–1107.
- 14Gillen D, Wirz AA, Ardill JE, et al. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999; 116: 239–247.
- 15Fossmark R, Johnsen G, Johanessen E, et al. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 2005; 21: 149–154.
- 16Sandvik AK, Brenna E, Waldum HL. Review article: the pharmacological inhibition of gastric acid secretion-tolerance and rebound. Aliment Pharmacol Ther 1997; 11: 1013–1018.
- 17Orenstein SR. Infantile reflux: different from adult reflux. Am J Med 1997; 103: 114S–119S.
- 18Rudolph CD, Mazur LJ, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001; 32(Suppl 2): S1–S31.
- 19Barr RG. Excessive crying. In: AJ Sameroff, M Lewis, SM Miller, editors. Handbook of Developmental Psychopathology. 2nd ed New York: Kluwer Academic; 2000. pp. 327–350.
10.1007/978-1-4615-4163-9_18 Google Scholar
- 20Hassall E, et al. Omeprazole for maintenance therapy of erosive esophagitis in children. Gastroenterology 2000; 118: A658.
- 21Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 2007; 150: 262–267.
- 22Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006; 117: e817–e820.
- 23Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294: 2989–2995.
- 24Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 1955–1960.
- 25Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004; 57: 422–428.
- 26Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947–2953.
- 27Saiman L, Ludington E, Dawson JD, et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001; 20: 1119–1124.
- 28Guillet R, Stoll BJ, Cotton CM, et al. Association of H2 blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2006; 117: e137–e142.
- 29Orenstein SR, Gremse DA, Pantaleon CD, et al. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children. Clin Ther 2005; 27: 472–483.
Citing Literature
